ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0180

Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis

Attila Feher1, Nabil Boutagy1, Evangelos Oikonomou1, Stephanie Thorn1, Yi-Hwa Liu1, Edward Miller1, Albert Sinusas1 and Monique Hinchcliff2, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Westport, CT

Meeting: ACR Convergence 2021

Keywords: Imaging, Microvascular dysfunction, PET, Raynaud's phenomenon, Scleroderma, Systemic

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Imaging of Rheumatic Diseases Poster (0149–0182)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: To investigate the association between Raynaud phenomenon (RP) and coronary microvascular dysfunction, we measured myocardial flow reserve (MFR) using positron emission tomography/computed tomography (PET/CT) in patients with primary and secondary RP and controls.

Methods: Patients with RP and matched controls who underwent dynamic rest-stress 82-Rubidium PET/CT from 09/2012-09/2019 for evaluation of chest pain or dyspnea were studied. Differences in heart rate-blood pressure product corrected MFR and clinical predictors of reduced MFR (< 2.0) were determined (Figure 1.).

Results: 49 patients (80% female, 65 ± 11 years) with RP (11 with primary RP, 18 with systemic sclerosis (SSc) and 20 with other autoimmune diagnoses (AID, n=6 systemic lupus erythematosus, n=6 rheumatoid arthritis, n=4 overlap syndrome, n=2 Sjogren’s syndrome, n=2 inflammatory arthritis), 49 patients without RP matched for age, gender and cardiovascular co-morbidities (78% female, 64 ± 13 years) and 14 healthy controls (50% female, 35 ± 5 years) were studied. Primary RP patients, healthy participants and matched control patients had comparable MFR (Figure 2.). In secondary RP patients, only those with underlying SSc had significantly reduced MFR (1.62 ± 0.32) compared to healthy participants (p=0.01, 2.22 ± 0.44) and to matched controls (p=0.03, 2.06 ± 0.61). In univariate (Fig 3A) and multivariable logistic regression (Figure 3B), only SSc was a significant predictor of reduced MFR. We have also identified a correlation between time since autoimmune disease diagnosis and MFR (r= -0.37; 95% CI: -0.61 to -0.09; p=0.01).

Conclusion: Our findings suggest that only secondary, not primary, RP is associated with reduced MFR, and that SSc-RP patients have reduced MFR compared to primary RP and other autoimmune disease patients. Larger prospective studies are warranted to fully elucidate the prognostic value of MFR in patients with secondary RP.

Fig1.jpeg”

Figure 1. Representative relative perfusion images, time activity curves and myocardial blood flow (MBF) values obtained at stress (Str) and rest (Rst) for a patient with systemic sclerosis (A) and for a healthy control subject (B). Perfusion imaging showed no perfusion defects, however for the systemic sclerosis patient blood flow quantification revealed global reduction in stress myocardial blood flow and myocardial flow reserve (<2.0) whereas the healthy control subject had normal myocardial blood flow values. SA: short axis, HLA: horizontal long axis, VLA: vertical long axis, LV: left ventricle, RV: right ventricle, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery.

Fig3.jpeg”

Figure 2. Stress myocardial blood flow (MBF) in healthy controls, matched control patients without Raynaud phenomenon (RP) and in patients with primary RP, secondary RP with autoimmune disease (AID) other than systemic sclerosis (SSc) and in patients with SSc.

Fig4.jpeg”

Figure 3. Forest plot of odds ratios (OR) of clinical predictors of reduced myocardial flow reserve (MFR <2.0) in univariate (A) and multivariate (B) regression models. BMI: body mass index, RP: Raynaud phenomenon, CT: computed tomography, PET: positron emission tomography, CI: confidence interval.


Disclosures: A. Feher, None; N. Boutagy, None; E. Oikonomou, None; S. Thorn, None; Y. Liu, None; E. Miller, None; A. Sinusas, None; M. Hinchcliff, None.

To cite this abstract in AMA style:

Feher A, Boutagy N, Oikonomou E, Thorn S, Liu Y, Miller E, Sinusas A, Hinchcliff M. Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impaired-myocardial-flow-reserve-on-82rubidium-positron-emission-computed-tomography-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impaired-myocardial-flow-reserve-on-82rubidium-positron-emission-computed-tomography-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology